HEE-GER: A systematic review of German economic evaluations of health care published 1990-2004

BMC Health Services Research

Volumn 7, Issue , 2007, Pages

  Schwappach, David L B ^a,b   Boluarte, Till A ^b  

^a Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; ECONOMIC EVALUATION; GERMANY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; LITERATURE; METHODOLOGY; PUBLIC HEALTH; PUBLICATION; QUALITY OF LIFE; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; BIBLIOGRAPHIC DATABASE; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION STUDY; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DATABASES, BIBLIOGRAPHIC; DELIVERY OF HEALTH CARE; EVALUATION STUDIES AS TOPIC; GERMANY; HEALTH SERVICES RESEARCH; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN;

EID: 33846600940     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-7-7     Document Type: Article

References (43)

1. Growth and Quality of the Cost-Utility Literature, 1976-2001. PJ Neumann D Greenberg NV Olchanski PW Stone AB Rosen, Value Health 2005 8 3 9 10.1111/j.1524-4733.2005.04010.x 15841889
2. Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability. M Barbieri M Drummond R Willke J Chancellor B Jolain A Towse, Value Health 2005 8 10 23 10.1111/j.1524-4733.2005.03070.x 15841890
3. Quality of abstracts of papers reporting original cost-effectiveness analyses. AB Rosen D Greenberg PW Stone NV Olchanski PJ Neumann, Med Decis Making 2005 25 424 428 10.1177/0272989X05278932 16061894
4. Measuring costs in cost-utility analyses. Variations in the literature. PW Stone RH Chapman EA Sandberg B Liljas PJ Neumann, Int J Technol Assess Health Care 2000 16 111 124 10.1017/S0266462300161100 10815358
5. Problems with the interpretation of pharmacoeconomic analyses. SR Hill AS Mitchell DA Henry, JAMA 2000 283 2116 2121 10.1001/jama.283.16.2116 10791503
6. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. JA Doshi HA Glick D Polsky, Value Health 2006 9 334 340 10.1111/j.1524-4733.2006.00122.x 16961551
7. Its in your hands: the value of handsearching in conducting systematic reviews of public health interventions. R Armstrong N Jackson J Doyle E Waters F Howes, J Public Health (Oxf) 2005 27 388 391 10.1093/pubmed/fdi056 16311247
8. Challenges in systematic reviews of economic analyses. M Pignone S Saha T Hoerger KN Lohr S Teutsch J Mandelblatt, Ann Intern Med 2005 142 1073 1079 15968032
9. Searching literature databases for health care economic evaluations: how systematic can we afford to be? F Sassi L Archard D McDaid, Med Care 2002 40 387 394 10.1097/00005650-200205000-00004 11961473
10. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. G Richardson A Manca, Health Econ 2004 13 1203 1210 10.1002/hec.901 15386669
11. What should be reported in a methods section on utility assessment? PF Stalmeier MK Goldstein AM Holmes L Lenert J Miyamoto AM Stiggelbout GW Torrance J Tsevat, Med Decis Making 2001 21 200 207 10.1177/02729890122062497 11386627
12. Stata Corp, Stata Statistical Software: Release 9.0 College Station, TX: Stata Corporation 2005
13. The measurement of observer agreement for categorical data. JR Landis GG Koch, Biometrics 1977 33 159 174 10.2307/2529310 843571
14. The estimation of a preference-based measure of health from the SF-36. J Brazier J Roberts M Deverill, J Health Econ 2002 21 271 292 10.1016/S0167- 6296(01)00130-8 11939242
15. Converting visual acuity to utilities. S Sharma GC Brown MM Brown GK Shah K Snow H Brown H Hollands, Can J Ophthalmol 2000 35 267 272 10959467
16. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. GW Torrance DH Feeny WJ Furlong RD Barr Y Zhang Q Wang, Med Care 1996 34 702 722 10.1097/00005650- 199607000-00004 8676608
17. Twenty years of health care economic analysis in Spain: are we doing well? A Garcia-Altes, Health Econ 2001 10 715 729 10.1002/hec.608 11747053
18. Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care: 1997-2001. JE Siegel SC Byron WF Lawrence, Value Health 2005 8 223 236 10.1111/j.1524-4733.2005.04037.x 15877594
19. Can we better prioritize resources for cost-utility research? PJ Neumann AB Rosen D Greenberg NV Olchanski R Pande RH Chapman PW Stone S Ondategui-Parra J Nadai JE Siegel, Med Decis Making 2005 25 429 436 10.1177/0272989X05276853 16061895
20. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. J Lexchin LA Bero B Djulbegovic O Clark, BMJ 2003 326 1167 1170 12775614 10.1136/bmj.326.7400.1167
21. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. M Friedberg B Saffran TJ Stinson W Nelson CL Bennett, JAMA 1999 282 1453 1457 10.1001/jama.282.15.1453 10535436
22. Quantitative analysis of sponsorship bias in economic studies of antidepressants. CB Baker MT Johnsrud ML Crismon RA Rosenheck SW Woods, Br J Psychiatry 2003 183 498 506 10.1192/bjp.183.6.498 14645020
23. Selective COX-2 inhibitors: a health economic perspective. DL Schwappach CM Koeck, Wien Med Wochenschr 2003 153 116 122 10.1046/j.1563-258X.2003.03006.x 12705064
24. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. KS Knox JR Adams B Djulbegovic TJ Stinson C Tomor CL Bennet, Ann Oncol 2000 11 1591 1595 10.1023/A:1008309817708 11205468
25. Bias in published cost effectiveness studies: systematic review. CM Bell DR Urbach JG Ray A Bayoumi AB Rosen D Greenberg PJ Neumann, BMJ 2006 332 699 703 16495332 10.1136/bmj.38737.607558.80
26. C Pritchard, Developments in economic evaluation in health care: A review of HEED London: Office of Health Economics (OHE) 2004
27. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. I Griebsch J Coast J Brown, Pediatrics 2005 115 e600 e614 10.1542/peds.2004-2127 15867026
28. The quality of published cost-utility analyses, 1976-1997. PJ Neumann PW Stone RH Chapman EA Sandberg CM Bell, Ann Intern Med 2000 132 964 972 10858180
29. Are Methods for estimating QALYs in cost-effectiveness analyses improving? PJ Neumann DE Zinner JC Wright, Med Decis Making 1997 17 402 408 9343798
30. Raising the quality of cost-utility analyses: lessons learnt and still to learn. K Gerard I Smoker J Seymour, Health Policy 1999 46 217 238 10.1016/S0168-8510(98)00061-X 10351669
31. Validating the EQ-5D with time trade off for the German population. W Greiner C Claes JJ Busschbach JM Graf von der Schulenburg, Eur J Health Econ 2004 15614535
32. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. X Badia M Roset M Herdman P Kind, Med Decis Making 2001 21 7 16 11206949
33. Comparison of Finnish and U.S.-based visual analog scale valuations of the EQ-5D measure. JA Johnson A Ohinmaa B Murti H Sintonen SJ Coons, Med Decis Making 2000 20 281 289 10929850
34. Estimating an EQ-5D population value set: the case of Japan. A Tsuchiya S Ikeda N Ikegami S Nishimura I Sakai T Fukuda C Hamashima A Hisashige M Tamura, Health Econ 2002 11 341 353 10.1002/hec.673 12007165
35. Validating the EQ-5D with time trade off for the German population. W Greiner C Claes JJ Busschbach JM Graf von der Schulenburg, Eur J Health Econ 2004 15614535
36. Modeling valuations for EuroQol health states. P Dolan, Med Care 1997 35 1095 1108 10.1097/00005650-199711000-00002 9366889
37. A single European currency for EQ-5D health states. Results from a six-country study. W Greiner T Weijnen M Nieuwenhuizen S Oppe X Badia J Busschbach M Buxton P Dolan P Kind P Krabbe, Eur J Health Econ 2003 4 222 231 10.1007/s10198-003-0182-5 15609189
38. Validating the EQ-5D with time trade off for the German population. W Greiner C Claes JJ Busschbach JM Graf von der Schulenburg, Eur J Health Econ 2005 6 124 130 10.1007/s10198-004-0264-z
39. Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses. CA Brauer AB Rosen D Greenberg PJ Neumann, Value Health 2006 9 213 218 10.1111/j.1524-4733.2006.00116.x 16903990
40. Diffusion of published cost-utility analyses in the field of health policy and practice. SS Sonnad D Greenberg AB Rosen PJ Neumann, Int J Technol Assess Health Care 2005 21 399 402 16110721
41. Preference-based outcome measures in cost-utility analyses. A 20-year overview. D Greenberg JS Pliskin, Int J Technol Assess Health Care 2002 18 461 466 12391940
42. The Diffusion of Health Economics Knowledge in Europe: The EURONHEED (European Network of Health Economics Evaluation Database) Project. G de Pouvourville P Ulmann J Nixon S Boulenger J Glanville M Drummond, Pharmacoeconomics 2005 23 113 120 10.2165/00019053-200523020-00003 15748086
43. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project. J Nixon P Ulmann J Glanville S Boulenger M Drummond PG de, Eur J Health Econ 2004 5 183 187 15452755